

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Assignee: Arcaris, Inc.

Inventors: Carl Alexander Kamb, et al

Application No: 09/259,155

Filed: February 26, 1999

For: PROCESS FOR IDENTIFICATION OF  
GENES, PERTURBAGENS AND  
CELLULAR TARGETS RELATING TO  
VIRAL GROWTH AND DISEASE

Group Art Unit: 1655  
Examiner: Jeffrey N. Fredman

Certificate of Mailing/Transmission( 37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is, on the  
date shown below, being:

**MAILING**

[ ] deposited with the United States Postal Service as First  
Class Mail on the date indicated below in an envelope  
addressed to the Assistant Commissioner for Patents,  
Washington, D.C. 20231

**FACSIMILE**

[X] transmitted by facsimile to the Patent and Trademark  
Office with confirming copy via First Class Mail

Date: November 10, 2000

Type or Print Name of Person Mailing: Laura Handley

Signature of Person Mailing

**SUPPLEMENTAL PRELIMINARY AMENDMENT**

Sir:

This is a preliminary amendment to **Application No. 09/259,155**. On February 18, 2000, the Examiner issued an Office Action, and on August 15, 2000 Applicant filed a Response and Amendment. Applicant's representative discussed the case with the Examiner on November 6, 2000. Claims 1-9, 11 and 13 are pending.

**AMENDMENT**

Please CANCEL claim 5.

Please AMEND the claims as follows:

1. (Twice Amended) A method for identifying a proteinaceous perturbagen that inhibits viral growth-related cell death, comprising the steps of:
  - (a) introducing a library of [perturbagen encoding] nucleic acids, each library member encoding a perturbagen within a scaffold structure, into a population of host cells;
  - (b) expressing the encoded proteinaceous perturbagens within said scaffold structure in said population of host cells;

- (c) exposing said perturbagen-bearing host cell population to a virus;
- (d) selecting for growth-proficient cells; and
- (e) recovering from said growth-proficient cells a sublibrary of nucleic acids encoding perturbagens that confer inhibition of viral growth-related cell death.

2. (Reiterated) The method of claim 1, wherein said step of selecting for growth-proficient cells comprises detecting cells that are not productively infected with said virus.

3. (Reiterated) The method of claim 2, wherein said step of detection comprises detection of non-fluorescent cells.

4. (Reiterated) The method of claim 1, wherein said step of selecting for growth-proficient cells comprises a stringent selection for growth.

5. (Cancelled) [The method of claim 1, wherein said proteinaceous perturbagen is expressed in a scaffold.]

6. (Amended) The method of claim [5] 1, wherein said scaffold is non-fluorescing GFP.

7. (Reiterated) The method of claim 1 wherein said virus is selected from a group consisting of rhinovirus, reovirus, influenza virus, adenovirus, human immunodeficiency virus, human papilloma virus, hepatitis virus and herpes virus.

8. (Reiterated) The method of claim 7 wherein said virus is human immunodeficiency virus.

9. (Amended; reiterated) A method for identifying a cell proliferation gene or gene fragment that inhibits viral growth-related cell death, comprising the steps of:

- (a) introducing a library of putative cell proliferation genes or gene fragments into a population of host cells;
- (b) expressing said library in said population of host cells;
- (c) exposing said library-bearing host cell population to a virus;
- (d) selecting for growth-proficient cells; and
- (e) recovering from said growth-proficient cells a sublibrary of cell proliferation genes or gene fragments that confer inhibition of viral growth-related cell death.

11. (Amended; reiterated) A method for identifying a cellular target involved in viral growth within a cell, comprising the steps of:

- (a) exposing in a protein interaction assay (i) a perturbagen obtained by the method of claim 1 to (ii) a population of putative cellular targets obtained from said growth-proficient cells; and
  - (b) identifying a cellular target that interacts with said perturbagen.
13. (Amended; reiterated) The method of claim 11, wherein said step of identifying comprises a yeast two-hybrid interaction assay.

### CONCLUSION

Applicant requests that the Examiner enter and consider favorably the claims as amended and submitted herein.


**Please address all TELEPHONIC communication to Laura A. Handley, the undersigned attorney of Arcaris, Inc., at (801) 303-0304.**

Please address all **WRITTEN** communication to the following:

Barbara A. Ruskin  
Fish & Neave  
1251 Avenue of the Americas  
New York, New York 10020  
(212) 596-9000

Date: November 10, 2000

Respectfully submitted,

By:   
\_\_\_\_\_  
Laura A. Handley  
Registration No. 39,704

Arcaris, Inc.  
615 Arapeen Drive, Suite 300  
Salt Lake City, Utah 84108  
Telephone: (801) 303-0300  
Telefax: (801) 303-0333